@LifeScienceNx

Connecting and driving collaboration in Pharma and Biotech communities #Pharma #Biotech

 London, England
LifeScienceNetworks.com
Joined February 2023
  • Tweets1.5K
  • Following194
  • Followers22
1Media
Life Science Networks retweeted
PharmaSource@ThePharmaSource20 Jun 2023
Staying a step ahead of the drug counterfeiters: how pharma procurement teams can protect #supplychain integrity w/ @Rx_360 The latest podcast is out now pharmasource.global/content/…
1
68
Life Science Networks retweeted
PharmaSource@ThePharmaSource31 May 2023
"Most Chief Data Officers focus on the Data Lake. But it gets polluted over time and quickly becomes a data swamp as there’s still trash coming in every day through the river." Johannes Galatsanos @Novartis Listen to the latest episode: linkedin.com/feed/update/urn…
1
68
Life Science Networks retweeted
PharmaSource@ThePharmaSource25 May 2023
How does a 200 year-old company continue to innovate? We spoke to Bormioli Pharma about their continuous #openinnovation process in the latest episode of PharmaSource podcast. Listed here or wherever you get your pods: open.spotify.com/show/1XQ07X…
2
164
NHS to introduce world-first genetic blood-matching test for transfusion treatments ift.tt/6NZK39E

NHS to introduce world-first genetic blood-matching test for transfusion treatments - PMLiVE

NHS Blood and Transplant will receive almost £1m in funding from NHS England

pmlive.com
35
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Award for Novel Cancer Immunotherapy Treatment | BioSpace ift.tt/Y2pHc9x

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Award for Novel Cancer Immunotherapy...

Ocean Biomedical (NASDAQ: OCEA ) announced today that its Scientific Co-founder, Dr. Jack A. Elias, MD, has been issued a broad patent for his cancer immunotherapy discovery related to reversing...

biospace.com
42
FDA Approves First Nasal Nalmefene Spray for Opioid Overdose.   | BioSpace ift.tt/NLMXa4z
44
Researchers asking for AI regulations, in this week's R&D Power Index - Research & Development World ift.tt/9zDcUIh

Researchers asking for AI regulations, in this week's R&D Power Index - Research & Development World

The R&D World Index (RDWI) for the week ending May 19, 2023, closed at 2,737.80 for the 25 companies in the RDWI.

rdworldonline.com
21
Pfizer’s maternal RSV vaccine candidate backed by FDA advisory committee ift.tt/TFMe1x8
22
Krystal Biotech Announces $160 Million Private Placement Equity Financing | BioSpace ift.tt/JB8ywgK

Krystal Biotech Announces $160 Million Private Placement Equity Financing

Krystal Biotech, Inc. today announced that it has entered into a securities purchase agreement for the sale of 1,729,729 shares of its common stock at $92.50 per share in a private placement (the...

biospace.com
34
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B | BioSpace ift.tt/r7aenou

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for...

Centessa Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SerpinPC, an investigational novel inhibitor of activated protein C...

biospace.com
44
2022 Prescription Trends ift.tt/e4rT0PS

2022 Prescription Trends | PharmExec

The market for prescription medicines in the United States was subject to major shifts in use across therapeutic areas in 2022, reflecting changes in patient health needs, the development, and...

pharmexec.com
12
Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate ift.tt/QbM3FPv

Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in...

Milestone Pharmaceuticals Inc. today announced promising data from an ad hoc analysis of a subset of patients experiencing atrial fibrillation with rapid ventricular rate (AFib-RVR) in the NODE-303...

biospace.com
28
Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences | BioSpace ift.tt/e8jlWtM

Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences

Seelos Therapeutics, Inc. today announced that it will participate in two upcoming healthcare conferences.

biospace.com
15
Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat | BioSpace ift.tt/cwoXkA1

Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat

The 61-patient study met the primary endpoint of improved physiologic liver function and secondary endpoints, which included established non-alcoholic steatohepatitis biomarkers, Hepion reported...

biospace.com
15
ReNAgade debuts with $300M and an ‘all-in-one’ system for delivering RNA drugs ift.tt/HAREgN2

ReNAgade debuts with $300M and an ‘all-in-one’ system for delivering RNA drugs

Staffed by former Alnylam and Moderna employees, the startup is developing technologies that could be useful in a variety of RNA drugmaking methods.

biopharmadive.com
12
China’s NMPA accepts IND for SinoMab BioScience’s SM17 ift.tt/Bh8F4X3

China’s NMPA accepts IND for SinoMab BioScience’s SM17

The CDE of China’s NMPA has accepted an investigational new drug application (IND) for SinoMab BioScience’s SM17 to treat asthma.

pharmaceutical-technology.com
10
Beta Bionics wins FDA nod to challenge Medtronic for automated insulin pump market ift.tt/7fM1DEi

Beta Bionics wins FDA nod to challenge Medtronic for automated insulin pump market

Beta Bionics’ device, aimed at people with Type 1 diabetes, has eliminated most of the data entry required by competitors.

medtechdive.com
19
Thermo Fisher gets FDA clearance for first blood test of severe preeclampsia risk ift.tt/Qb3xc6S

Thermo Fisher gets FDA clearance for first blood test of severe preeclampsia risk

A study found the test is a better predictor of the risk of developing preeclampsia with severe features than standard clinical measures.

medtechdive.com
9
Extending Botulinum Treatments ift.tt/q6zXlud
18
Phase III Results Prime Dupixent as First Potential Biologic Approval for COPD | BioSpace ift.tt/KCPpX5n

Phase III Results Prime Dupixent as First Potential Biologic Approval for COPD

Sanofi and Regeneron reported positive results for the anti-inflammatory drug in a chronic obstructive pulmonary disease trial. The companies hope to see approval before a 2024 read-out of a second...

biospace.com
67
Load more